Testing anti-Zika virus NS1 IgA additionally to IgM increases sensitivity in acutely infected patients from regions endemic for flaviviruses

K. Steinhagen, N. Wilhelm, J.M. Warnecke, and W. Schlumberger

Institute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany

Introduction
Specific IgM response to Zika virus (ZIKV) can be low or absent in patients with acute ZIKV infection and a history of other infections with related flaviviruses, e.g. dengue virus (DENV), presenting with an early high IgG titer. In these ZIKV cases, IgA against ZIKV non-structural protein 1 (NS1) was observed in the acute phase, suggesting anti-ZIKV IgA as alternative acute marker in secondary infections. In this study, we investigated the diagnostic benefit of an ELISA for combined detection of virus-specific IgA/IgM compared to IgM only.

Methods
The following human serum panels were included in this study:
1) A sensitivity panel (panel 1) comprising acute serum samples (day 8-16 post symptom onset) of 31 residents from the Dominican Republic (2015), where ZIKV and DENV are endemic. Patients had been tested positive for ZIKV nucleic acid and anti-DENV IgG during the viraemic phase (≤ day 5).
2) A specificity panel (panel 2) consisting of serum samples (day 3-7 post symptom onset) of 40 Vietnamese patients, hospitalised with DENV haemorrhagic fever according to the World Health Organization case definition grade I and tested positive for DENV nucleic acid and anti-DENV IgG. Vietnam (2015) is endemic for DENV but not for ZIKV.

Anti-ZIKV NS1 antibodies were determined in each sample using a commercial NS1-based Anti-Zika virus ELISA IgM (Euroimmun AG, Germany) and a corresponding ELISA (Euroimmun), applying a combination of anti-human IgA/IgM conjugated with peroxidase.

Results
In panel 1, 29% (9/31) of samples were positive for anti-ZIKV NS1 IgM, whereas 100% were positive for combined specific IgA and IgM. In panel 2, none of the sera reacted in the Anti-Zika virus ELISA IgM, two samples were reactive in the Anti-Zika virus IgAM ELISA (5.0%).

Conclusion
Since patients with acute ZIKV infection from flavivirus endemic regions may not develop NS1-specific antibodies of class IgM, additional testing of anti-ZIKV NS1 IgA is required.